URMC Partners with Indivumed Friday, February 05, 2016 The University of Rochester Medical Center announced it’s collaborating with Indivumed, a Germany-based company, to establish a bank of human tissues and tumor samples that are expertly preserved and stored for use in cancer research.Bile Acid Supports Production of Blood Stem Cells Thursday, February 04, 2016 A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.New Biomarker to Assess Stem Cells Developed Wednesday, February 03, 2016 A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.ReNeuron Receives US Patent on Cell Cryopreservation Technology Wednesday, February 03, 2016 ReNeuron Group is pleased to announce that it has received a Notice of Allowance from the US Patent and Trademark Office for a key patent application covering its cell cryopreservation technology. Tricked-Out Immune Cells Could Attack Cancer Wednesday, February 03, 2016 New cell-engineering technique may lead to precision immunotherapies.Adaptimmune, GSK Expand Strategic Immunotherapy Collaboration Wednesday, February 03, 2016 Adaptimmune Therapeutics and GlaxoSmithKline announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer program, an affinity enhanced T-cell immunotherapy (GSK3377794) targeting NY-ESO-1, toward pivotal trials in synovial sarcoma. Cell Therapy Catapult is now the Cell and Gene Therapy Catapult Wednesday, February 03, 2016 New name reflects mandate of the Catapult to serve the industry.
Illumina Signs Multiple Biobank Deals Wednesday, February 03, 2016 MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Sernova Announces Agreement with CCRM Friday, January 29, 2016 CCRM to establish, optimize and validate methods for producing Sernova’s transformative cell-based therapies for Type-1 diabetes.